- 516 consecutive patients with early breast cancer who received APBI. The mean age of the participants was 66 years and median follow-up was 4.9 years.
-The basal and HER-2 subtype patients had higher histologic grades, larger tumors, and were more likely to have received chemotherapy
-At 5 years, ipsilateral breast tumor recurrence rates ranged from 0.0% to 4.8%, but were not significantly different among the subtypes. Distant metastasis was seen only in the luminal A (2.5%) and luminal B (1.4%) subtypes (P = .87).
- The researchers concluded that "5-year local control rates after treatment with APBI are excellent for luminal, HER2, and triple-negative phenotypes of early-stage breast cancer. Further study of breast cancer subtypes is important and may be useful when counseling patients on adjuvant treatment options following breast-conserving surgery."
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.